SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to positive third-quarter financial results, with revenue and EPS exceeding expectations, sparking bullish sentiment. The community is discussing the company's AI integration and potential beyond just gaming, as well as the growth of Unity Vector. Some investors see the recent earnings as a sign of improved execution and an attractive adtech/fintech ecosystem.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as the community discusses the ongoing bidding war with Pfizer for Metsera, with some questioning the aggressive pursuit given NVO's existing pipeline and others speculating about potential impacts on competition. Community members are also analyzing recent earnings and forward guidance, weighing the potential of upcoming FDA approvals against concerns about management strategy and competition from Eli Lilly.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart ($UPST) is trending amidst discussions around its Q3 earnings and future prospects; while some express concerns about the company's business model and potential risks related to loan performance, others point to positive growth metrics and potential for a short squeeze. Community members are debating whether the recent price action reflects market manipulation or genuine concerns about the company's fundamentals, particularly in light of broader economic uncertainties and the performance of comparable fintech companies. The stock's high short interest and upcoming earnings are fueling speculation about a potential squeeze.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind ($MNKD) is trending due to recent quarterly results showing increased Afrezza sales and royalties, alongside the completed acquisition of scPharmaceuticals. The community is actively discussing the potential impact on future coverage from Morgan Stanley and Goldman Sachs, as well as updates on clinical trials and revenue projections. Some investors are expressing frustration with the stock's movement despite positive news.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as the community rallies around the meme coin, emphasizing its resilience and strong community. Talk centers around the coin's ability to hold strong despite market liquidations, with participants highlighting the coin's real-world partnerships and sponsorships. The community uses the phrase "that slaps" to express excitement and are focused on onboarding new users to crypto through IRL events.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid mixed sentiment following recent Q3 earnings and key strategic updates, including reaffirmed timelines for the R2 launch and the introduction of Mind Robotics. While some community members express bullish views on long-term potential, others remain skeptical about profitability and execution, particularly regarding the R2's success. Discussions also revolve around Rivian's positioning in the EV market relative to competitors like Tesla, as well as potential impacts from partnerships and industry trends.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending amidst analyst optimism and community discussion around its growth strategy, particularly highlighting Needham's updated rating to "Buy". Investors are contrasting ZETA's acquisition approach with other AI players and anticipating an upgrade cycle, while also noting the company's OpenAI partnership. The community is actively debating fundamentals and potential price movements, with some focusing on its ability to quietly add enterprise clients and deliver measurable growth.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending due to community discussion around a potential buyout offer from Nestle following recent financial results and business updates; the lack of confirmation from the company regarding buyout rumors is fueling speculation and frustration, as investors debate the likelihood of a deal versus a partnership or other strategic alternatives. Disappointment from a recent conference call has also added to investor unease, as some feel management danced around key questions about rumors of a buyout offer and future capital needs.

DigitalOcean Holdings, Inc. engages in the provision of providing cloud infrastructure. It operates through the following geographical segments: United States, Netherlands, Germany, Canada, Singapore, and Other. The company was founded in 2012 and is headquartered in Broomfield, CO.

DigitalOcean Holdings Inc

DigitalOcean ($DOCN) is trending as investors react positively to strong earnings, with revenue growth and AI initiatives driving excitement. The community highlights the company's focus on SMBs and its potential as an acquisition target, fueling discussions about its long-term growth prospects. Bullish sentiment is further supported by positive analyst ratings and price target increases.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid political chatter and election outcomes, with community members debating the stock's valuation and its ties to narratives and emotion rather than fundamentals. Some traders are pointing to the stock's volatility, while others are highlighting alternative investments with stronger data or enterprise growth. The broader discussion includes contrasting perspectives on the political climate and potential impacts on the market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.

Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline

Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.75, marking a -5.89% move from the previous day.

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $6.36, moving 6.33% from the previous trading session.

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.23, representing a -5.42% change from its previous close.

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.98, representing a +1.32% change from its previous close.

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $4.77, signifying a -1.24% move from its prior day's close.

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Recursion Pharmaceuticals Inc - Ordinary Shares - Class A

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

RXRX
Recursion Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RXRX News

RXRXRecursion Pharmaceuticals Inc